These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32606594)

  • 1. Parenteral Sustained Release Lipid Phase-Transition System of Ziprasidone: Fabrication and Evaluation for Schizophrenia Therapy.
    Khan UA; Parveen U; Hasan N; Ahmed MZ; Saad S; Ahmad FJ; Jain GK
    Drug Des Devel Ther; 2020; 14():2237-2247. PubMed ID: 32606594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ziprasidone: the fifth atypical antipsychotic.
    Caley CF; Cooper CK
    Ann Pharmacother; 2002 May; 36(5):839-51. PubMed ID: 11978164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia.
    Stimmel GL; Gutierrez MA; Lee V
    Clin Ther; 2002 Jan; 24(1):21-37. PubMed ID: 11833834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.
    Gunasekara NS; Spencer CM; Keating GM
    Drugs; 2002; 62(8):1217-51. PubMed ID: 12010089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation and evaluation of ziprasidone-phospholipid complex from sustained-release pellet formulation with enhanced bioavailability and no food effect.
    Miao Y; Chen G; Ren L; Ouyang P
    J Pharm Pharmacol; 2016 Feb; 68(2):185-94. PubMed ID: 26748446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and therapeutics of acute intramuscular ziprasidone.
    Preskorn SH
    Clin Pharmacokinet; 2005; 44(11):1117-33. PubMed ID: 16231965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ziprasidone, a new atypical antipsychotic drug.
    Carnahan RM; Lund BC; Perry PJ
    Pharmacotherapy; 2001 Jun; 21(6):717-30. PubMed ID: 11401184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder.
    Gunasekara NS; Spencer CM; Keating GM
    CNS Drugs; 2002; 16(9):645-52. PubMed ID: 12153335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
    Zhang Y; Dai G
    Hum Psychopharmacol; 2012 Nov; 27(6):605-14. PubMed ID: 24446539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Scott LJ
    CNS Drugs; 2006; 20(12):1027-52. PubMed ID: 17140281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic.
    Daniel DG; Copeland LF
    Expert Opin Investig Drugs; 2000 Apr; 9(4):819-28. PubMed ID: 11060712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization and evaluation of self-nanoemulsifying sustained-release pellet formulation of ziprasidone with enhanced bioavailability and no food effect.
    Miao Y; Chen G; Ren L; Pingkai O
    Drug Deliv; 2016 Sep; 23(7):2163-2172. PubMed ID: 25148542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for successful clinical management of schizophrenia with ziprasidone.
    Fagiolini A; Cañas F; Gallhofer B; Larmo I; Levy P; Montes JM; Papageorgiou G; Zink M; Rossi A
    Expert Opin Pharmacother; 2010 Sep; 11(13):2199-220. PubMed ID: 20658947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials.
    Greenberg WM; Citrome L
    CNS Drug Rev; 2007; 13(2):137-77. PubMed ID: 17627670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ziprasidone, SCH23390 and SB277011 on spatial memory in the Morris water maze test in naive and MK-801 treated mice.
    Tanyeri P; Buyukokuroglu ME; Mutlu O; Ulak G; Akar FY; Celikyurt IK; Erden BF
    Pharmacol Biochem Behav; 2015 Nov; 138():142-7. PubMed ID: 26394282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction and evaluation of a phospholipid-based phase transition in situ gel system for brexpiprazole.
    Tao R; Liu L; Xiong Y; Zhang Q; Lv X; He L; Ren F; Zhou L; Chen B; Wu K; Zhang Y; Chen H
    Drug Deliv Transl Res; 2023 Nov; 13(11):2819-2833. PubMed ID: 37160629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice.
    Altamura AC; Sassella F; Santini A; Montresor C; Fumagalli S; Mundo E
    Drugs; 2003; 63(5):493-512. PubMed ID: 12600227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.